Acino snatches up Mepha/Teva divisions; India price caps fiercely opposed

  @FiercePharma: Bausch + Lomb eyes pharma ops expansion. Story | Follow @FiercePharma

> Swiss drugmaker Acino Pharma will acquire the Latin American and Asian businesses of Mepha AG, which is owned by Teva Pharmaceutical Industries ($TEVA). Acino will also buy the Mepha site in Aesch, Switzerland, although Teva will still grow the Mepha brand there, Reuters reports. Article

> India's plans to cap prices on 348 essential drugs and their combinations at the average price of the top three brands in their respective segments is drawing significant opposition. Piece

> Independent health experts say India must hike its drug spending by $4.5 billion, The Wall Street Journal reports. Story

> Reproductive rights advocates may revive a dormant federal lawsuit in New York to challenge Plan B restrictions. Item

> The market for multiple myeloma drugs will grow 5.6% annually from 2010 to 2020, a Decision Resources report concludes. Release

Biotech News

@FierceBiotech: The top 10 biotech deal terminations of 2011. GSK/Targacept break-up takes top spot. Report | Follow @FierceBiotech

@JohnCFierce: Somaxon axing staffers, calling in the "strategic advisers." Anyone want to buy a sleep drug? Release | Follow @JohnCFierce

@RyanMFierce: Cornell U. won a competition involving Stanford and NYU to be NYC's pick to set up a science grad school in Gotham. Item | Follow @RyanMFierce

@MaureenFierce: Using neti pots for sinus relief could cause amoebas to eat your brain. News | Follow @MaureenFierce

@MarkHFierce: There's a way now to keep a cancer patient's healthy cells and tumor cells alive in the lab. Two ingredients help. Release | Follow @MarkHFierce

> Trius shares surge as antibiotic matches Zyvox in pivotal PhIII. News

> Russian billionaire bankrolls early-stage biotech VC group. Story

> Burrill raises $313M for new life sciences venture fund. More

> Alexza readies "significant" layoffs, brings in Lazard to review asset sale. Article

Medical Device News

> Lawmakers seek recall info from Medtronic, 4 others. News

> TransEnterix closes $15M in 2nd tranche of Series B. Article

> CSA scores $20.5M in Series B. More

> FDA looks to improve the representation of women in device studies. Story

Biotech IT News

> Blood cancer group lights way to 28% faster trial starts. Item

> Elsevier scoops up scientific software outfit Ariadne. Story

> Harvard plays money ball with biotech--and baseball--data. Article

> EU program backs Linguamatics and ChemAxon's informatics work. News

And Finally... Drinking enough alcohol to become drunk significantly increases aggression in people who focus on the here and now, without thinking about the impact on the future, according to Brad Bushman, lead author of the study and professor of communication and psychology at Ohio State University. Story

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.